Pliant Therapeutics Inc. (PLRX)
1.15
0.00 (0.00%)
Upcoming Events
Latest Headlines
Pliant Therapeutics to present cancer drug data at ASCO meeting
May 21, 2026 5:36 PM - StreetInsider
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026 5:29 PM - Globe NewsWire
Atisama advances RB042 to phase 1 multi-dose study, names new board chair
May 15, 2026 10:25 AM - StreetInsider
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
May 15, 2026 10:25 AM - PR NewsWire
Form 10-Q PLIANT THERAPEUTICS, For: Mar 31
May 11, 2026 4:11 PM - SEC Filing
Form 8-K PLIANT THERAPEUTICS, For: May 11
May 11, 2026 4:08 PM - SEC Filing
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 11, 2026 4:05 PM - StreetInsider
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 6, 2026 8:30 AM - Globe NewsWire
Pliant Therapeutics doses first patient in cancer trial expansion
April 30, 2026 8:30 AM - StreetInsider
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
April 30, 2026 8:30 AM - StreetInsider
Form ARS PLIANT THERAPEUTICS, For: Dec 31
April 22, 2026 4:33 PM - SEC Filing
Form DEFA14A PLIANT THERAPEUTICS,
April 22, 2026 4:32 PM - SEC Filing
Form DEF 14A PLIANT THERAPEUTICS, For: Jun 11
April 22, 2026 4:32 PM - SEC Filing
Pliant reports updated Phase 1 data for PLN-101095 cancer treatment
April 18, 2026 1:31 PM - StreetInsider
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
April 18, 2026 1:31 PM - StreetInsider
Form 4 PLIANT THERAPEUTICS, For: Apr 17 Filed by: Kuo Minnie
April 17, 2026 4:43 PM - SEC Filing
Form 4 PLIANT THERAPEUTICS, For: Apr 17 Filed by: Coulie Bernard
April 17, 2026 4:43 PM - SEC Filing
Form 4 PLIANT THERAPEUTICS, For: Apr 17 Filed by: Cummings Keith Lamont
April 17, 2026 4:43 PM - SEC Filing
Form 4 PLIANT THERAPEUTICS, For: Apr 17 Filed by: Cheung Lily
April 17, 2026 4:43 PM - SEC Filing
Form 8-K PLIANT THERAPEUTICS, For: Apr 14
April 17, 2026 4:31 PM - SEC Filing
Form EFFECT PLIANT THERAPEUTICS,
April 7, 2026 12:37 PM - SEC Filing
Form S-3 PLIANT THERAPEUTICS,
March 30, 2026 5:59 PM - SEC Filing
Form 8-K PLIANT THERAPEUTICS, For: Mar 27
March 30, 2026 5:48 PM - SEC Filing
Pliant Therapeutics to present phase 1 trial data at AACR meeting
March 18, 2026 9:00 AM - StreetInsider
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
March 18, 2026 9:00 AM - StreetInsider
Pliant Therapeutics (PLRX) PT Lowered to $3 at Canaccord
March 13, 2026 7:14 AM - StreetInsider
Pliant Therapeutics (PLRX) PT Lowered to $3 at Piper Sandler
March 12, 2026 9:20 AM - StreetInsider
Pliant Therapeutics, Inc. (PLRX) Tops Q4 EPS by 1c
March 11, 2026 4:48 PM - StreetInsider
Form S-8 PLIANT THERAPEUTICS,
March 11, 2026 4:33 PM - SEC Filing
Form 8-K PLIANT THERAPEUTICS, For: Mar 11
March 11, 2026 4:32 PM - SEC Filing
Form 10-K PLIANT THERAPEUTICS, For: Dec 31
March 11, 2026 4:29 PM - SEC Filing
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
March 11, 2026 4:05 PM - StreetInsider
Full Article List
